Developer docs
API playgroundTry for free, no card

Search company profiles

Stem Genomics

Full company profile

uuid000ymwq

Namestring
Stem Genomics
Legal namestring
Stem Genomics
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Stem Genomics is a French-based specialty life sciences services company founded in 2018 as a spin-out from the Institute for Regenerative Medicine and Biotherapy (IRMB) in Montpellier. The company provides genomic stability testing for human pluripotent stem cells (hPSCs) and human mesenchymal stromal cells (hMSCs), addressing a quality control gap that traditional G-Banding karyotyping cannot fill due to its inability to detect sub-karyotypic abnormalities and its slow, expensive workflow. Its core technology is a proprietary digital PCR (dPCR) probe panel covering 24-28 genomic regions responsible for more than 90% of recurrent copy number variations in hPSCs and more than 80% in hMSCs, including the sub-karyotypic 20q11.21 amplification that accounts for over 20% of hPSC abnormalities globally. The flagship iCS-digital™ PSC assay delivers results in 2-3 days with a published false-positive rate of 0.098%, positioning it as a faster, lower-cost, higher-resolution alternative to G-Banding for in-process cell culture QC.

The company's commercial offering operates through two channels: a full-service laboratory testing model (with ISO 9001:2015-certified labs in Grabels, France, and Durham, North Carolina, USA) and a direct-to-customer kit product line for laboratories with in-house dPCR instrumentation. The product portfolio has expanded beyond the original hPSC assay to include MSC, aneuploidy, 20q-only, STR cell line authentication, NGS-based Stem-Seq™, Pluri-digital™ pluripotency, and Myco-digital™ sterility tests, as well as a bundled one-stop-shop QC solution designed for ISSCR Standards compliance. Customers include academic core facilities (ICM, Karolinska, Harvard Ocular Genomics Institute, UMC Utrecht, University of Freiburg), cell therapy developers (GoLiver Therapeutics, DiNAQOR, Ncardia, denovoMATRIX), CRISPR gene editing services (EditCo Bio), and large life sciences organizations (Roche, I-Stem). Pricing is quote-based across both service and kit offerings. In 2024, Stem Genomics was acquired by Clean Cells, a strategic acquirer in cell therapy quality control, joining that group to expand combined US presence and regulatory-aligned QC capabilities.

Short descriptiontext

Stem Genomics provides digital PCR-based genomic stability testing services and kits for human pluripotent and mesenchymal stem cells, serving academic researchers, cell therapy developers, and gene editing biotechs with rapid QC assays that detect sub-karyotypic abnormalities G-Banding misses.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGrabels, France
HQ citystring
Grabels
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic stability testing, stem cell characterization, digital PCR assays, cell line authentication, pluripotent stem cell QC
Industry1 code
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code3 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Genomic Stability Testing Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Laboratory testing services (full service)
TypeProfessional Services
Description

Stem Genomics performs tests in its own laboratories (France and USA) using its proprietary assays. Customers ship cell samples or DNA to Stem Genomics and receive results within 2-3 days for dPCR-based tests.

stemgenomics.com
2Digital PCR kit products (iCS-digital™ PSC kit, iCS-digital™ MSC kit, 20q-only)
TypeOne Time License
Description

Sale of proprietary digital PCR kit products for clients who have in-house dPCR instrumentation. The kits include multiplexed PCR assays and validated control DNA. Accompanied by proprietary iCS-digital™ software for data analysis. Revenue is generated per kit transaction.

stemgenomics.com
3Customized assay development
TypeProfessional Services
Description

Stem Genomics offers bespoke assay development services tailored to specific customer requirements and cell types, beyond the standard product menu.

stemgenomics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Full-service laboratory testing (送样检测服务)
ModelOtherBilling cadencePay-as-you-go
Notes

Customers ship samples to Stem Genomics labs; Stem Genomics performs the assay and returns results. Pricing is quote-based and not publicly listed.

stemgenomics.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1iCS-digital™ PSC
Description

Digital PCR-based assay for monitoring hPSC genome integrity, detecting more than 90% of recurrent genomic abnormalities in human pluripotent stem cells

stemgenomics.com
+6 more records
Core offering1 text field

Stem Genomics provides laboratory services and proprietary kits for assessing the genetic integrity of human pluripotent stem cells (hPSCs) and human mesenchymal stromal cells (hMSCs). Its core offerings are digital PCR-based assays (iCS-digital™ PSC, iCS-digital™ MSC, iCS-digital™ Aneuploidy) for rapid detection of copy number variations and recurrent genomic abnormalities, complemented by G-Banding karyotyping, NGS-based Stem-Seq™ assays, STR cell line authentication, Pluri-digital pluripotency testing, and Myco-digital sterility testing. Customers can either ship samples to the company's ISO 9001:2015-certified labs in France or the US, or purchase kit products to run the tests in-house.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 28.5% of hPSC samples tested by Stem Genomics using iCS-digital™ PSC are found to have genomic abnormalities
+6 more records
Product overview1 text field

Stem Genomics offers a comprehensive portfolio of genomic stability testing solutions for stem cell research, centered on proprietary digital PCR-based assays (iCS-digital™ product line) and supplemented by traditional cytogenetic services. The core offering includes iCS-digital™ PSC (for pluripotent stem cells), iCS-digital™ MSC (for mesenchymal stromal cells), and iCS-digital™ Aneuploidy tests, available as both laboratory services and in-house kits. The product range extends to G-Banding karyotyping, NGS-based Stem-Seq™ assays, STR cell line authentication, Pluri-digital pluripotency testing, and Myco-digital sterility testing. Customers can purchase individual tests, the combined Duo iCS-Karyo service, or a comprehensive one-stop-shop bundle. The company operates from France (headquarters) and the USA (Durham, NC laboratory).

Product and service5 records
1iCS-digital™ PSC
CategoryGenomic Stability Testing
Description

Digital PCR-based assay for detecting genomic abnormalities in human pluripotent stem cells (hPSCs), using a panel of 24-28 probes covering more than 90% of recurrent copy number variations and delivering results in 2-3 days. Available as a full-service laboratory offering or as an in-house kit.

2iCS-digital™ PSC Kit
CategoryGenomic Stability Testing
Description

In-house digital PCR kit version of the iCS-digital™ PSC test, enabling laboratories with dPCR instrumentation to perform genomic stability testing of hPSCs independently, accompanied by the proprietary iCS-digital™ software for analysis.

3iCS-digital™ PSC 20q-only Kit
CategoryGenomic Stability Testing
Description

Specialized digital PCR kit targeting specifically the 20q11.21 amplification, which represents more than 20% of recurrent genomic abnormalities in hPSCs.

4iCS-digital™ MSC
CategoryGenomic Stability Testing
Description

Digital PCR-based assay for monitoring genomic stability of human mesenchymal stromal cells (hMSCs), with 24 probes targeting all human chromosomes and detecting more than 80% of the most frequent genetic abnormalities in hMSCs.

5iCS-digital™ Aneuploidy
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Pluristyx, described as a leading one-stop-shop solution provider for high-quality cell-based therapies, serves as a channel partner for Stem Genomics' products, expanding reach into the cell therapy ecosystem.

Strategic tierMajorTypeOthers
Description

Clean Cells, a cell therapy quality control company, acquired Stem Genomics in 2024 to strengthen cell therapy quality control capabilities and expand US presence. This is an acquisition (M&A) rather than a commercial partnership.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Netherlands-based hiPSC technology company providing cardiovascular and neuronal cell products and services to drug discovery customers; long-standing Stem Genomics client and partner operating in the same hiPSC QC ecosystem.

TypeDirect peer
Description

One-stop-shop solution provider for high-quality cell-based therapies and a Channel Partner of Stem Genomics; offers iPSC banking and QC services that overlap directly with Stem Genomics' offering.

TypeBroad incumbent
Description

Global contract laboratory testing services group with deep cell and molecular biology capabilities; a broad incumbent in lab testing services with the scale to compete on cell-line characterization and genomic stability offerings.

TypeDirect peer
Description

Denmark-based partner of Stem Genomics offering hiPSC-derived cell products and services for research and drug discovery, mirroring the hiPSC-services and disease-modeling focus.

TypeBroad incumbent
Description

Large life-sciences tools company offering cytokines, media, and stem cell QC reagents including karyotyping/STR services; a broad incumbent with overlapping capabilities in stem cell characterization workflows.

TypeDirect peer
Description

Wisconsin-based nonprofit that provides human pluripotent stem cell banking, distribution, and characterization services — one of the most established hPSC characterization labs globally and a direct comparator in stem cell QC and authentication services.

TypeDirect peer
Description

Provider of iPSC-derived hepatocytes and disease models for drug discovery; operates in the same iPSC-services space where QC of starting material is a recurring requirement, making it a comparable niche player.

TypeBroad incumbent
Description

Japan-headquartered iPSC and stem cell services company with global footprint offering cell products, banking, and QC-adjacent services; broader catalogue than Stem Genomics but overlapping in iPSC characterization.

TypeBroad incumbent
Description

Major commercial iPSC supplier and drug discovery services provider under Fujifilm; large-scale incumbent in the same iPSC market segment, with internal QC needs that intersect with Stem Genomics' value proposition.

10EditCo Bio
TypeDirect peer
Description

Provider of CRISPR-edited cell lines (including iPSCs) for research and therapeutic applications; a named customer of Stem Genomics and a peer in the CRISPR QC + iPSC services workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stem Genomics

Genomic Stability Testing Servicesstemgenomics.com

Stem Genomics provides digital PCR-based genomic stability testing services and kits for human pluripotent and mesenchymal stem cells, serving academic researchers, cell therapy developers, and gene editing biotechs with rapid QC assays that detect sub-karyotypic abnormalities G-Banding misses.

What Stem Genomics does

Stem Genomics is a French-based specialty life sciences services company founded in 2018 as a spin-out from the Institute for Regenerative Medicine and Biotherapy (IRMB) in Montpellier. The company provides genomic stability testing for human pluripotent stem cells (hPSCs) and human mesenchymal stromal cells (hMSCs), addressing a quality control gap that traditional G-Banding karyotyping cannot fill due to its inability to detect sub-karyotypic abnormalities and its slow, expensive workflow. Its core technology is a proprietary digital PCR (dPCR) probe panel covering 24-28 genomic regions responsible for more than 90% of recurrent copy number variations in hPSCs and more than 80% in hMSCs, including the sub-karyotypic 20q11.21 amplification that accounts for over 20% of hPSC abnormalities globally. The flagship iCS-digital™ PSC assay delivers results in 2-3 days with a published false-positive rate of 0.098%, positioning it as a faster, lower-cost, higher-resolution alternative to G-Banding for in-process cell culture QC.

The company's commercial offering operates through two channels: a full-service laboratory testing model (with ISO 9001:2015-certified labs in Grabels, France, and Durham, North Carolina, USA) and a direct-to-customer kit product line for laboratories with in-house dPCR instrumentation. The product portfolio has expanded beyond the original hPSC assay to include MSC, aneuploidy, 20q-only, STR cell line authentication, NGS-based Stem-Seq™, Pluri-digital™ pluripotency, and Myco-digital™ sterility tests, as well as a bundled one-stop-shop QC solution designed for ISSCR Standards compliance. Customers include academic core facilities (ICM, Karolinska, Harvard Ocular Genomics Institute, UMC Utrecht, University of Freiburg), cell therapy developers (GoLiver Therapeutics, DiNAQOR, Ncardia, denovoMATRIX), CRISPR gene editing services (EditCo Bio), and large life sciences organizations (Roche, I-Stem). Pricing is quote-based across both service and kit offerings. In 2024, Stem Genomics was acquired by Clean Cells, a strategic acquirer in cell therapy quality control, joining that group to expand combined US presence and regulatory-aligned QC capabilities.

Stem Genomics firmographics

Firmographics
Name
Stem Genomics
Legal name
Stem Genomics
Website
https://stemgenomics.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
11–50 employees
Short description
Stem Genomics provides digital PCR-based genomic stability testing services and kits for human pluripotent and mesenchymal stem cells, serving academic researchers, cell therapy developers, and gene editing biotechs with rapid QC assays that detect sub-karyotypic abnormalities G-Banding misses.
Ownership category
akta.pro rank

Stem Genomics industry classification

Industry
Product category
Genomic Stability Testing Services
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Genomic stability testing
  • Stem cell characterization
  • Digital PCR assays
  • Cell line authentication
  • Pluripotent stem cell QC

Where Stem Genomics is headquartered

Location

Headquarters

HQ city
Grabels
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Stem Genomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Laboratory testing services (full service): Stem Genomics performs tests in its own laboratories (France and USA) using its proprietary assays. Customers ship cell samples or DNA to Stem Genomics and receive results within 2-3 days for dPCR-based tests.
  2. Digital PCR kit products (iCS-digital™ PSC kit, iCS-digital™ MSC kit, 20q-only): Sale of proprietary digital PCR kit products for clients who have in-house dPCR instrumentation. The kits include multiplexed PCR assays and validated control DNA. Accompanied by proprietary iCS-digital™ software for data analysis. Revenue is generated per kit transaction.
  3. Customized assay development: Stem Genomics offers bespoke assay development services tailored to specific customer requirements and cell types, beyond the standard product menu.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goFull-service laboratory testing (送样检测服务)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Stem Genomics product offering

Product offering

Core offering

Stem Genomics provides laboratory services and proprietary kits for assessing the genetic integrity of human pluripotent stem cells (hPSCs) and human mesenchymal stromal cells (hMSCs). Its core offerings are digital PCR-based assays (iCS-digital™ PSC, iCS-digital™ MSC, iCS-digital™ Aneuploidy) for rapid detection of copy number variations and recurrent genomic abnormalities, complemented by G-Banding karyotyping, NGS-based Stem-Seq™ assays, STR cell line authentication, Pluri-digital pluripotency testing, and Myco-digital sterility testing. Customers can either ship samples to the company's ISO 9001:2015-certified labs in France or the US, or purchase kit products to run the tests in-house.

Product overview

Stem Genomics offers a comprehensive portfolio of genomic stability testing solutions for stem cell research, centered on proprietary digital PCR-based assays (iCS-digital™ product line) and supplemented by traditional cytogenetic services. The core offering includes iCS-digital™ PSC (for pluripotent stem cells), iCS-digital™ MSC (for mesenchymal stromal cells), and iCS-digital™ Aneuploidy tests, available as both laboratory services and in-house kits. The product range extends to G-Banding karyotyping, NGS-based Stem-Seq™ assays, STR cell line authentication, Pluri-digital pluripotency testing, and Myco-digital sterility testing. Customers can purchase individual tests, the combined Duo iCS-Karyo service, or a comprehensive one-stop-shop bundle. The company operates from France (headquarters) and the USA (Durham, NC laboratory).

Differentiator

Problem solved

Functional benefit

Brands

  • iCS-digital™ PSC: Digital PCR-based assay for monitoring hPSC genome integrity, detecting more than 90% of recurrent genomic abnormalities in human pluripotent stem cells
  • iCS-digital™ MSC
  • iCS-digital™ Aneuploidy
  • Duo iCS-Karyo
  • Pluri-digital™
  • Stem-Seq™
  • Myco-digital

Products and services

  • iCS-digital™ PSC Digital PCR-based assay for detecting genomic abnormalities in human pluripotent stem cells (hPSCs), using a panel of 24-28 probes covering more than 90% of recurrent copy number variations and delivering results in 2-3 days. Available as a full-service laboratory offering or as an in-house kit.
  • iCS-digital™ PSC Kit In-house digital PCR kit version of the iCS-digital™ PSC test, enabling laboratories with dPCR instrumentation to perform genomic stability testing of hPSCs independently, accompanied by the proprietary iCS-digital™ software for analysis.
  • iCS-digital™ PSC 20q-only Kit Specialized digital PCR kit targeting specifically the 20q11.21 amplification, which represents more than 20% of recurrent genomic abnormalities in hPSCs.
  • iCS-digital™ MSC Digital PCR-based assay for monitoring genomic stability of human mesenchymal stromal cells (hMSCs), with 24 probes targeting all human chromosomes and detecting more than 80% of the most frequent genetic abnormalities in hMSCs.
  • iCS-digital™ Aneuploidy

Quantifiable outcome

  • 28.5% of hPSC samples tested by Stem Genomics using iCS-digital™ PSC are found to have genomic abnormalities
  • +6 more outcomes

Companies that use Stem Genomics

Customer profile

Named customers11 records

Segments4 records

Ideal customer profiles4 records

Stem Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

Stem Genomics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and major.

  • PluristyxcoreChannel Partner/ Reseller/ DistributorPluristyx, described as a leading one-stop-shop solution provider for high-quality cell-based therapies, serves as a channel partner for Stem Genomics' products, expanding reach into the cell therapy ecosystem.
  • Clean CellsmajorOthersClean Cells, a cell therapy quality control company, acquired Stem Genomics in 2024 to strengthen cell therapy quality control capabilities and expand US presence. This is an acquisition (M&A) rather than a commercial partnership.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Stem Genomics competitors and assessment

Company assessment

Direct peers

  • Ncardia: Netherlands-based hiPSC technology company providing cardiovascular and neuronal cell products and services to drug discovery customers; long-standing Stem Genomics client and partner operating in the same hiPSC QC ecosystem.
  • Pluristyx: One-stop-shop solution provider for high-quality cell-based therapies and a Channel Partner of Stem Genomics; offers iPSC banking and QC services that overlap directly with Stem Genomics' offering.
  • Bioneer: Denmark-based partner of Stem Genomics offering hiPSC-derived cell products and services for research and drug discovery, mirroring the hiPSC-services and disease-modeling focus.
  • WiCell: Wisconsin-based nonprofit that provides human pluripotent stem cell banking, distribution, and characterization services — one of the most established hPSC characterization labs globally and a direct comparator in stem cell QC and authentication services.
  • DefiniGEN: Provider of iPSC-derived hepatocytes and disease models for drug discovery; operates in the same iPSC-services space where QC of starting material is a recurring requirement, making it a comparable niche player.
  • EditCo Bio: Provider of CRISPR-edited cell lines (including iPSCs) for research and therapeutic applications; a named customer of Stem Genomics and a peer in the CRISPR QC + iPSC services workflow.

Broad incumbents

  • Eurofins Scientific: Global contract laboratory testing services group with deep cell and molecular biology capabilities; a broad incumbent in lab testing services with the scale to compete on cell-line characterization and genomic stability offerings.
  • Bio-Techne: Large life-sciences tools company offering cytokines, media, and stem cell QC reagents including karyotyping/STR services; a broad incumbent with overlapping capabilities in stem cell characterization workflows.
  • Reprocell: Japan-headquartered iPSC and stem cell services company with global footprint offering cell products, banking, and QC-adjacent services; broader catalogue than Stem Genomics but overlapping in iPSC characterization.
  • Cellular Dynamics International (Fujifilm CDI): Major commercial iPSC supplier and drug discovery services provider under Fujifilm; large-scale incumbent in the same iPSC market segment, with internal QC needs that intersect with Stem Genomics' value proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Stem Genomics social profiles

Digital presence

Stem Genomics compliance and trust

Trust signal

Compliance1 record

Stem Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stem Genomics leadership team

Management profile

Number of profiles

Profiles4 records

Stem Genomics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stem Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stem Genomics

What does Stem Genomics do?

Stem Genomics provides laboratory services and proprietary kits for assessing the genetic integrity of human pluripotent stem cells (hPSCs) and human mesenchymal stromal cells (hMSCs). Its core offerings are digital PCR-based assays (iCS-digital™ PSC, iCS-digital™ MSC, iCS-digital™ Aneuploidy) for rapid detection of copy number variations and recurrent genomic abnormalities, complemented by G-Banding karyotyping, NGS-based Stem-Seq™ assays, STR cell line authentication, Pluri-digital pluripotency testing, and Myco-digital sterility testing. Customers can either ship samples to the company's ISO 9001:2015-certified labs in France or the US, or purchase kit products to run the tests in-house.

Is Stem Genomics a public or private company?

Stem Genomics is a private company. It is classified as corporate owned and is currently acquired.

When was Stem Genomics founded?

Stem Genomics was founded in 2018. It employs 11 to 50 people.

Where is Stem Genomics based?

Stem Genomics is headquartered in Grabels, France, in the Europe region.

How does Stem Genomics make money?

Three revenue lines are on record. Laboratory testing services (full service) is the primary driver. The others are digital PCR kit products (iCS-digital™ PSC kit, iCS-digital™ MSC kit, 20q-only) and customized assay development.

Who are Stem Genomics's main competitors?

Direct peers on record are Ncardia, Pluristyx, Bioneer, WiCell, DefiniGEN and EditCo Bio. Broad incumbents are Eurofins Scientific, Bio-Techne, Reprocell and Cellular Dynamics International (Fujifilm CDI).

Does Stem Genomics have an API?

No public API is recorded for Stem Genomics.

What industry is Stem Genomics in?

Stem Genomics's product category is Genomic Stability Testing Services. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals